Other substances

6D3

A cross-reactive monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

6D3 is an anti-staphylococcal enterotoxin B monoclonal antibody. It was observed to inhibit SARS-CoV-2 cell entry in vitro. The antibody possibly targets S1/S2 site on the Spike protein (Cheng et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Spike protein In vitro Antibody 		Vero E6 cells; SARS-CoV-2 Isolate USA-WA1/2020 4.86

Inhibits SARS-CoV-2 cell entry in vitro.

 Apr/29/2021

AI-suggested references

Link Publication date
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Oct/15/2020
Export (.csv)